Skip to content
Screener

Zymeworks ZYME Interest Expense And Amortization Related to Sale of Future Royalties

Interest Expense And Amortization Related to Sale of Future Royalties at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$17.35M-6.2%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$17.51M-6.1%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$65.7M+32.3%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%
Geron logo
GeronGERN
$20.69M+18.6%
Geron logo
GeronGERN
$20.69M+18.6%

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Operating income-$42.2M-6,158%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.7B+83.2%
Enterprise value$1.54B+81.1%
P/S45.8×+38.3×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept zyme:InterestExpenseAndAmortizationRelatedToSaleOfFutureRoyalties.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations(42,180)(674)(89,298)(26,287)
Other (expense) income:
Interest income3,2873,4265,9986,850
Interest expense related to sale of future royalties(6,595)(8,661)
Other income (expense), net196(621)316(572)
Total other (expense) income, net(3,112)2,805(2,347)6,278
(Loss) income before income taxes(45,292)2,131(91,645)(20,009)
Income tax recovery (expense)2731862,464(310)

Item 1. Financial Statements

FAQ

What is Zymeworks's interest expense and amortization related to sale of future royalties?
Zymeworks (ZYME) reported interest expense and amortization related to sale of future royalties of $6.6M in Q2 2026.
What does interest expense and amortization related to sale of future royalties mean?
Interest Expense And Amortization Related to Sale of Future Royalties as reported by Zymeworks Inc..

Ask your AI about Zymeworks's interest expense and amortization related to sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude